Anti-IL-5 therapy with mepolizumab reduced annualized moderate–severe exacerbations when added to triple therapy in eosinophil-high COPD (MATINEE phase 3), providing confirmatory evidence for IL-5 pathway inhibition in appropriately enriched populations [96]. The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.